DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Apple Restores Telegram to App Store After Content Policy Violation 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Jetstar to Charge for Overhead Cabin Bags From February 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
GAITHERSBURG, Md., March 20, 2018 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursday, March 29.
| Conference Call Details | |||
| Date: | Thursday, March 29 | ||
| Time: | 8:30am Eastern Time | ||
| Domestic: | 866-548-4713 | ||
| International: | 323-794-2093 | ||
| Conference ID: | 6280732 | ||
| Webcast: | http://public.viavid.com/index.php?id=128569 | ||
| Replays, Available through April 12th: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 6280732 | ||
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
[email protected]
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
[email protected]
